The price of Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares last traded on Wall Street unchanged to $1.28.
DNA stock price is now -25.22% away from the 50-day moving average and -23.27% away from the 200-day moving average. The market capitalization of the company currently stands at $2.50B.
In other news, Kelly Jason R, insider sold 100,000 shares of the company’s stock on Nov 09. The stock was sold for $129,100 at an average price of $1.29. Upon completion of the transaction, the insider now directly owns 5,294,680 shares in the company, valued at $6.78 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 09, Shetty Reshma P. sold 37,650 shares of the business’s stock. A total of $48,531 was realized by selling the stock at an average price of $1.29. This leaves the insider owning 12,600,444 shares of the company worth $16.13 million. Insiders disposed of 36,609,057 shares of company stock worth roughly $46.86 million over the past 1 year. A total of 35.10% of the company’s stock is owned by insiders.
A candlestick chart of Ginkgo Bioworks Holdings Inc (NYSE: DNA) showed a price of $1.3500 on Monday morning. During the past 12 months, Ginkgo Bioworks Holdings Inc has had a low of $1.12 and a high of $2.94. As of last week, the company has a debt-to-equity ratio of 0.32, a current ratio of 6.78, and a quick ratio of 6.78. The fifty day moving average price for DNA is $1.7118 and a two-hundred day moving average price translates $1.6681 for the stock.
The latest earnings results from Ginkgo Bioworks Holdings Inc (NYSE: DNA) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.16, missing analysts’ expectations of -$0.09 by -0.07. This compares to -$0.41 EPS in the same period last year. The net profit margin was -272.30% and return on equity was -63.83% for DNA. The company reported revenue of $55.43 million for the quarter, compared to $66.4 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -16.52 percent. For the current quarter, analysts expect DNA to generate $42.37M in revenue.
